S100B (S100 Calcium-Binding Protein B) is a key homodimeric cytokine and intracellular regulator predominantly expressed by astrocytes. Extracellularly, S100B acts as a damage-associated molecular pattern (DAMP) signaling molecule, interacting with the Receptor for Advanced Glycation Endproducts (RAGE) and TLR4 to drive inflammatory cascades, neurodegeneration, and oncogenic pathways in melanoma. Developing selective therapeutics targeting S100B requires highly purified, conformationally stable antigens to navigate the high sequence homology within the S100 family.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for S100B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human S100B Protein (Homodimer) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Native conformation preserved via calcium-optimized buffer. |
View S100B Products |
| Gene Delivery | S100B Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View S100B Products |
| Benchmark Ab | Anti-S100B Recombinant Positive Control Antibody High-affinity sequence-verified clone for assay validation and benchmark screening. |
View S100B Products |
| Validator | S100B siRNA Set For target knockdown verification and specificity profiling. |
View S100B Products |
| Related Target A | RAGE (AGER) Primary extracellular receptor for S100B; essential for S100B-RAGE axis blocking assays. |
View RAGE Products |
| Related Target B | S100A1 High-homology family member; crucial for counter-screening and selectivity profiling. |
View S100A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent conformational shifts | Buffer-optimized recombinant S100B preserving physiological calcium-binding capacity. |
| High homology off-target risk (S100 family) | Purified S100 family panel (S100A1, S100A6, S100A8/A9) strictly verified by mass spectrometry for selectivity screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in cellular assays | Validated siRNA included for specificity checks |
Live S100B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for S100B therapeutics is intensifying, with major players shifting focus from traditional diagnostic biomarker applications to active therapeutic targeting in neuroinflammatory diseases and oncology. Extracellular S100B acts as a potent pro-inflammatory driver in the brain microenvironment, prompting the development of neutralizing monoclonal antibodies and small-molecule inhibitors to disrupt the S100B-RAGE axis. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective S100B inhibitors that do not cross-react with other S100 proteins like S100A1, preventing potential cardiotoxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biopharma | Traumatic Brain Injury, Neurodegeneration, Stroke | Neutralization Assay (Need high-purity, low-endotoxin S100B homodimer) |
| Small Molecule Inhibitors | Oncology Startups, Universities | Metastatic Melanoma, Glioma | Binding Pocket Selectivity (Need S100B vs S100A1 mutant/WT comparative screening) |
| Diagnostic / Companion Dx | Roche, Abbott, DiaSorin | Melanoma Staging, Mild Cognitive Impairment | High-affinity, stable antigen for sandwich ELISA calibrators |